GENE ONLINE|News &
Opinion
Blog

2021-08-10| China

China Allows Trials to Evaluate Mixing and Matching of INOVIO, Sinovac Vaccines

by Tyler Chen
Share To

To quickly vaccinate the global population, several biotech companies have launched clinical trials to examine the efficacy and safety of mixing COVID-19 vaccines. So, a second shot of the same vaccine wouldn’t be necessary for the vaccination to remain effective.

 

Mixing a DNA and an Inactivated Vaccine

On August 9th, China allowed Inovio to conduct two clinical trials mixing its DNA vaccine, INO-4800, and the WHO-approved inactivated vaccine, Sinovac’s CoronaVac. The trials will investigate the safety, tolerability, and immunogenicity of the combination.

In fact, the mixing of INO-4800 and CoronaVac have already been examined in animal models. Results show increased levels of antigen-specific binding antibodies, neutralizing antibodies by both live-virus neutralization assay and hACE2 receptor blocking assay, and antigen-specific T cell immune responses.

 

INO-4800’s Clinical Progress

Currently, INO-4800 has entered the Phase 3 segment of the Phase 2/3 INNOVATE trial. The global trial will take place in countries in Latin America, Asia, and Africa. According to Phase 1 and 2 trials, INO-4800 could generate a strong CD8 T cell level against the Delta variant and induce balanced T cells and B cells immune response.

The strongest suit of INO-4800 lies in its ability to be stable at room temperature for over 1 year and at 37°C for 1 week, alleviating the cold chain requirements in transportation. Together with the anti-Delta variant activity, INO-4800 could be the primary and booster dose and able to reach every corner of the world, conducting vaccination in tougher conditions.

 

Mixing of Pfizer and AZ Vaccines

As for other such studies, the mixing of AstraZeneca vaccine (ChAdOx1-S, Vaxzevria) and Pfizer vaccine (BNT162b2, Comirnaty) are proven to increase neutralizing antibodies substantially compared to taking 2 doses of ChAdOx1-S. And patients only showed mild to moderate levels of adverse events, which is a positive safety profile.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
GSK Secures Approval From Chinese NMPA for Nucala, its Add-On-Therapy to Treat CRSwNP
2025-01-07
HUTCHMED China Secures USD$ 608 Million in Strategic 45% Shanghai Operations Divestment
2025-01-02
BIOSECURE Act Absent in Key U.S. Defense Bill—Slim Chance of Passing December 20 Resolution
2024-12-20
LATEST
Neuro, Pain, and Cancer Top the List at JPM 2025 Healthcare Conference
2025-01-17
ZYN Nicotine Pouches Receive FDA Marketing Authorization
2025-01-17
Virginia’s Insurance Marketplace Extends Open Enrollment Deadline: A Detailed Report
2025-01-16
2025 Starts with a Jolt: Layoffs Hit the Life Sciences Industry Ahead of JPM
2025-01-16
Eli Lilly Steals the Spotlight at JPM 2025 with $2.5 Billion Power Move Acquisition
2025-01-16
Pre-JPM 2025: The Quiet Deals You May Have Missed Before the Big Show
2025-01-16
JPM 2025’s Billion Dollar Deal – GSK Bids Big in GI Cancer
2025-01-15
EVENT
2025-02-05
Precision Medicine World Conference 2025
Santa Clara, California
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top